35 articles for JL Methot
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Potent benzoazepinone¿-secretase modulators with improved bioavailability.

Merck Research Laboratories
Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.

Merck Research Laboratories
Triazoloamides as potent¿-secretase modulators with reduced hERG liability.

Merck Research Laboratories
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Merck Research Laboratories
Triazoles as¿-secretase modulators.

Merck Research Laboratories
SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Merck Research Laboratories
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.

Merck Research Laboratories
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1

Merck
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors.

Merck
Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.

Merck
Discovery of a new series of PI3K-δ inhibitors from Virtual Screening.

Merck
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

Merck
Identification of Potent Reverse Indazole Inhibitors for HPK1.

Merck
Optimization of Versatile Oxindoles as Selective PI3Kδ Inhibitors.

Merck
Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.

Merck
Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.

Merck
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow.

Merck
Structure Overhaul Affords a Potent Purine PI3Kδ Inhibitor with Improved Tolerability.

TBA
Discovery of novel triazolobenzazepinones as γ-secretase modulators with central Aβ42 lowering in rodents and rhesus monkeys.

Merck Research Laboratories Boston
COMPOUND BASED ON QUINAZOLINE-SUBSTITUTED GLUTARIMIDE SKELETON AND USE THEREOF

Gluetacs Therapeutics (Shanghai) Co.
Pharmaceutical compositions comprising heterocycle fused gamma carboline prodrugs

Intra-Cellular Therapies
ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS

Gilgamesh Pharmaceuticals
Pyrrole-substituted indolone derivative or pharmaceutically acceptable salts thereof, and preparation method therefor and application thereof

Suzhou Genhouse Pharmaceutical Co.
MODULATORS OF FPR1 AND METHODS OF USING THE SAME

Biofront
Potent Inhibition of SARS-CoV-2 nsp14

University of Montpellier
Compounds, compositions and methods

Denali Therapeutics
Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors

University of Michigan
Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors

UniversitÄT Duisburg-Essen
Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas

Celgene Quanticel Research
Aminoindazole derivatives as sodium channel inhibitors

Almirall
Hydroxylated aminotriazole derivatives as ALX receptor agonists

Actelion Pharmaceuticals
N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides

Novartis
A newly synthesized selective casein kinase I inhibitor, N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide, and affinity purification of casein kinase I from bovine testis.

Nagoya University School of Medicine
Synthesis and SAR exploration of dinapsoline analogues.

Bristol-Myers Squibb Pharmaceutical Research Institute
Cloning and characterization of the human GABAA receptor alpha 4 subunit: identification of a unique diazepam-insensitive binding site.

Cocensys